Tiffany Noyes, APRN
Payments from drug & device makers
Across 166 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Neurocrine Biosciences, Inc.$371
- Alkermes, Inc.$240
- Johnson & Johnson$222
- Teva Pharmaceuticals USA, Inc.$212
- AstraZeneca$135
- plus $842 from 19 others
What the payments were for
- Food & beverage$3,129100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 60 | $1,107 |
| Neurocrine Biosciences, Inc. | 15 | $371 |
| Alkermes, Inc. | 12 | $240 |
| Johnson & Johnson | 12 | $222 |
| Teva Pharmaceuticals USA, Inc. | 11 | $212 |
| AstraZeneca | 9 | $135 |
| Braeburn Inc. | 4 | $127 |
| Lundbeck LLC | 6 | $121 |
| Supernus Pharmaceuticals, Inc. | 5 | $99 |
| Otsuka America Pharmaceutical, Inc. | 5 | $94 |
| Indivior Inc. | 3 | $66 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $60 |
| Merck | 4 | $60 |
| Pfizer | 2 | $35 |
| Boehringer Ingelheim | 2 | $29 |
| Antares Pharma, Inc. | 2 | $27 |
| Sunovion Pharmaceuticals Inc. | 2 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| GSK | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Axsome Therapeutics, Inc. | 1 | $12 |
| Lilly USA, LLC | 1 | $11 |
| Organon | 1 | $8 |
How this compares
$3,129 in reported general payments places this provider in the 85th percentile of 1,460 family providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 86 | $313,963 |
| IngrezzaValbenazine Tosylate | 26 | $203,844 |
| Austedo XrDeutetrabenazine | 37 | $191,985 |
| AristadaAripiprazole Lauroxil | 14 | $43,051 |
| LybalviOlanzapine/Samidorphan Malate | 21 | $32,103 |
| SpravatoEsketamine Hcl | 15 | $18,678 |
| QuviviqDaridorexant Hcl | 24 | $11,051 |
| TrintellixVortioxetine Hydrobromide | 16 | $9,826 |
| Paliperidone ErPaliperidone | 16 | $7,818 |
| FetzimaLevomilnacipran Hcl | 12 | $6,394 |
| InvegaPaliperidone | 12 | $6,320 |
| EligardLeuprolide Acetate | 13 | $6,088 |
| Olanzapine | 179 | $4,144 |
| Clozapine | 46 | $2,654 |
| Quetiapine Fumarate | 74 | $2,306 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Spravato, Invega | $222 | $338,961113 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $371 | $203,84426 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $212 | $191,98537 claims |
| Alkermes, Inc.Aristada, Lybalvi | $240 | $75,15435 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $16 | $11,05124 claims |
| AbbVieFetzima | $1,107 | $6,39412 claims |
| Lilly USA, LLCOlanzapine | $11 | $4,144179 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,460 family providers in Utah.
Other family in Price
- Riley WorthSandy$1.1M
- Katrina BawdenSalt Lake City$446K
- Cortnee RomanSalt Lake City$374K
- Jared ThorleySalt Lake City$368K
- Stephanie GodfreyLindon$358K
- Mary SteinbackSalt Lake City$189K
- Shannon FordSouth Jordan$186K
- Jennalyn MayeuxSalt Lake City$151K
- Brett RawlinsKaysville$149K
- Shelby MillerSandy$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.